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Abstract
Background: The antibiotics used for prophylaxis during surgery may influence the rate of surgical
site infections. Tetracyclines are attractive having a long half-life and few side effects when used in
a single dose regimen. We studied the rate of surgical site infections during changing regimens of
antibiotic prophylaxis in medium and major size surgery.
Methods: Prospective registration of surgical site infection following intestinal resections and
hysterectomies was performed. Possible confounding procedure and patient related factors were
registered. The study included 1541 procedures and 1489 controls. The registration included time
periods when the regimen was changed from doxycycline to cephalothin and back again.
Results: The SSI in the colorectal department increased from 19% to 30% (p = 0.002) when
doxycycline was substituted with cephalothin and decreased to 17% when we changed back to
doxycycline (p = 0.005). In the gynaecology department the surgical site infection rate did not
increase significantly. Subgroup analysis showed major changes in infections in rectal resections
from 20% to 35% (p = 0.02) and back to 12% (p = 0.003).
Conclusion: Doxycycline combined with metronidazole, is an attractive candidate for antibiotic
prophylaxis in medium and major size intestinal surgery.
Background
A high incidence of surgical site infections (SSIs) ranging
from 11% to 26% after elective colorectal surgery has been
reported by numerous authors during the last five years
[1-5]. The incidence in unselected patient series, including
urgent operations, patients with concurrent disease,
patients in whom preoperative infections were suspected
and patients with treatment failures is not known. Moder-
ate size surgical procedures, such as small intestinal sur-
gery and hysterectomies are followed by postoperative
infection rates around 5% to 10%, or lower in selected
elective cases [6-9]. About one half of the SSI becomes evi-
dent after discharge and the surgeons often do not know
the true infection rate [1,10].
Internationally, cephalosporins dominate as the preferred
group of drugs but several different regimens have been
studied in attempts to reduce SSI [11-14]. Combinations
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sides are widely used alternatives and newer drugs, such as
ertapenem, have also proved efficacious [3,15].
The decision on recommendations for antibiotic prophy-
laxis has to take many aspects into consideration. Factors
like tissue penetration, mechanism of antibacterial action,
half life in vivo, and protocol violation may be exchanged
by the simple consideration: Does it work in the clinical
everyday setting? It is important to consider the effect in
routine settings because prospective, randomized trials
will add focus on the topic, leading to a low degree of pro-
tocol violations and to results which might not reflect rou-
tine settings. Earlier reports have shown protocol
violations in up to 40% [1,12,16]. Other considerations
of importance are impact on bacterial resistance in the
hospital and community, side effects, especially allergic
reactions and induction of clinically important allergies.
As doxycycline is rarely used for therapeutic purposes in
hospitals, it becomes more interesting as a prophylactic
agent and it has been used in Norway for many years due
to the early works of Giercksky et al [17]. It shows no cross
allergy with more commonly used antibiotics, has a long
half-life of 16 to 18 hours and a fair price. In preoperative
prophylaxis one wants high antibacterial effect for a short
period of time and doxycycline may have been overseen
because it is bacteriostatic rather than bactericidal. Pro-
phylactic drugs with shorter half-life demand strict regi-
mens as to the timing of administration and drugs with
long half-life are probably advantageous in single-dose
regimens [18].
The aim of this study was to compare doxycycline and
metronidazole with cephalothin and metronidazole as
prophylactic agents against postoperative infections in an
unselected population of medium and major size surgery.
The analysis was performed in an everyday setting without
focus on compliance of protocols of administration.
Methods
The Department of Colorectal Surgery, and the Depart-
ment of Gynaecology and Obstetrics, both Haukeland
University Hospital, participated in the study. They are
separate units with a common policy of preoperative anti-
biotic prophylaxis and with a common surveillance sys-
tem of postoperative SSI. In the present study, we used
surveillance data for the period January 1st, 2004 through
February 29th, 2008. The Norwegian Social Science Data
Services and the local ethics committee approved the
study.
Surveillance data
Surveillance of SSI after selected surgical procedures is
mandatory in Norway with standardized collection of
data. SSI for the NOMESCO codes JFB (resection of small
or large intestine), JFH (colectomy), JFG (stoma and res-
ervoir operations), JGB (resection of the rectum), LCD
(excision of the uterus) and MCA 10 (elective, urgent or
emergency caesarean section) were registered prospec-
tively from January 1st, 2004.
A doctor registered SSI during hospital stay at discharge.
All patients were mailed a questionnaire for infectious
events 25-30 days after the operation. The patient ques-
tionnaire contained questions specific for signs of SSI and
recommended the patient to see a doctor if such signs
were evident. It also contained a questionnaire to the doc-
tor who diagnosed the infection. The patients, who did
not respond, received one reminder. Patients still hospi-
talized at the time of follow-up, were contacted and eval-
uated by Department of Infection Control for his/her
infection status.
SSI was defined as surgical site infection within 30 days
after the operation among those who were followed for 30
days. SSI was also categorized by degrees of severity as
superficial incision, deep incision, or organ specific infec-
tion using CDC-definitions [19]. All out-of-hospital infec-
tions, except superficial SSI, had to be confirmed by a
hospital department or a general practitioner. Patients
experiencing SSI during the hospitalization and again
after submission were registered as 2 separate events.
Patient related factors, such as age, gender and American
Society of Anaesthesiologists (ASA) score and urgency
were registered before the operation by the anesthesiolo-
gist. Procedure related factors, such as duration of the
operation, and procedure code were registered in the
operating theatre immediately after the operation. Emer-
gency operations were those that had to be initiated
within 2 hours from admission and urgent operations
within 24 hours. Duration of the operation was registered
as knife-time from incision to closure and as total time
from entrance to the operating room to exit. Categoriza-
tion of patients and procedure related variables are shown
in Additional File 1. All surveillance data were registered
electronically into databases managed by the Department
of Infection Control.
Antibiotics used for prophylaxis
Until July 31st 2006 the recommendation was 400 milli-
grams of doxycycline (Dumoxin®, Kipa Pharmacal Ltd.)
combined with 1.5 grams of metronidazole for intestinal
surgery and hysterectomies. By August 1st 2006,
Dumoxin® was withdrawn from the market due to manu-
facturing problems leading to loss of stability and reduced
durability of the drug. We therefore changed the regimen
to our second choice recommendation, which was 2.0
grams of the first generation cephalosporin cephalothinPage 2 of 7
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grams of metronidazole. For surgical procedures lasting
more than 3 hours, an additional dose of 2 grams of
cephalothin was recommended. No antibiotic prophylac-
tics were recommended for elective caesarean sections and
2 grams of cephalothin was recommended for emergency
and urgent sections throughout the entire study period.
The colorectal section registered an increase in SSI during
the beginning of 2007, and several procedures related to
SSI were scrutinized with no effect. By June 15st 2007, we
therefore changed the prophylactic regimen to another
commercially available doxycycline (Doxycycline®, Act-
avis). The department of Gynaecology and Obstetrics con-
tinued using cephalothin throughout the study period.
For the purpose of this study, a treatment variable with
three time periods was coded according to the time period
for which the various antibiotics were used (table 1). All
preoperative antibiotics were administered intravenously.
In the colorectal department the antibiotic infusion was
initiated in the ward immediately before the patient was
taken to the operation room and in the gynaecology
department the infusion was initiated one hour before the
patient was transferred to the operating theatre. The intes-
tinal operations were initiated 55 minutes after they left
the ward (mean time), except for rectal resections that had
an epidural catheter before surgery and the operation
started 75 minutes after they left the ward (mean time).
Patients
Initially, a total of 1882 procedures were performed and
1554 registrations (83%) were complete. Completeness
of registration in the colorectal unit was 78% to 84% dur-
ing the different periods. All resections of the small and
large intestine were registered including rectal resections,
but not appendectomies. In the gynaecology unit only
hysterectomies were registered. The completeness of regis-
tration was 87% to 91%. If a patient was registered with
the same surgical procedure more than once during the
study period, only the first procedure was included in the
study. This left us with a total of 1541 patients for analysis,
886 patients from the colorectal unit and 655 patients
from the gynaecology unit (table 2). In addition, both
elective and acute caesarean sections were included in the
study as controls (1489 patients).
Statistical analyses
All analyses were performed by using SAS (Statistical
Analysis System) version 9.1 for windows (SAS Institute,
Inc., Cary, North Carolina). All tests were two-sided and
p-values below 0.05 were considered statistical signifi-
cant. To examine if the incidence of SSI differed between
various time periods with different recommendations for
antibiotic prophylaxis, we used log-binomial regression
analyses. Time periods were included in the models as a
categorical variable, with cephalothin and metronidazole
period as reference. Differences between the reference
period and other time periods were measured by calculat-
ing crude and adjusted relative risks (RRs), with 95% con-
fidence intervals (CIs). Adjustment variables were age,
gender, surgical procedure, ASA score, urgency, time of
operation, and operation time (Additional File 1). P-val-
ues were obtained from chi-square tests.
Results
Frequency of infections
The period specific SSI rates for the various patient groups
are given in figure 1. Period 1 is the 30 months prior to the
shift of regimen from doxycycline and metronidazole to
cephalothin and metronidazole. In the colorectal unit
cephalothin was used during period 2 only, whereas it was
used during period 2 and 3 in hysterectomies. The obstet-
ric (control) patients did not change the antibiotic regi-
men during the study period.
For colorectal patients, the overall SSI rate increased from
18.9% to 29.6% (p = 0.002) during cephalothin prophy-
laxis as compared to doxycycline, and the high SSI rate
was reversed to 17.0% (p = 0.005) when we returned to
doxycycline in period 3 (figure 1). The SSI rate for gynea-
cology patients (i.e., hysterectomies) increased from
13.2% to 14.5% during the period of cephalothin proph-
ylaxis (p = 0.28).
Both elective and acute caesarean sections were included
into the registration (n = 1489). Elective caesarean sec-
tions received no antibiotic prophylactics in accordance
with national recommendations and acute sections were
recommended cephalothin only throughout the entire
period of registration. The SSI rate in both elective and
Table 1: Prophylactic antibiotic regimen according to patient group and period of observation
Patient groupa Period 1 Period 2 Period 3
Colorectal patients Doxycycline and metronidazole Cephalothin and metronidazole Doxycycline and metronidazole
Gynaecology patients Doxycycline and metronidazole Cephalothin and metronidazole Cephalothin and metronidazole
Patients with elective Caesarean section None None None
Patients with acute Caesarean section Cephalothin Cephalothin Cephalothin
a The colorectal and the gynaecological patients are the intervention groups and the acute and elective caesarean sections are the control group.Page 3 of 7
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ing the different periods of registration (figure 1).
Thirty-seven out of 63 rectal resections lasted more than 3
hours but only 27 of these patients received a second dose
of antibiotics.
The number of patients who had deep incision or organ
specific infections was too low for subgroup analysis
(Additional File 2).
Multivariate analysis
Table 3 shows crude and adjusted relative risks of SSI dur-
ing the cephalothin and metronidazole periods compared
to the doxycycline and metronidazole periods. There were
no significant differences in infection rates between the
time periods regarding hysterectomies (adjusted RR =
0.98, 95% CI: 0.64 - 1.49). A significant difference in SSI
between the different time periods was found in all com-
parisons of colorectal procedures (table 3). In general,
colorectal patients who had preoperative cephalothin and
metronidazole were more likely to experience infections
(overall adjusted RR = 1.61, 95% CI: 1.22 - 2.12), com-
pared with those who had doxycycline and metronida-
zole. Adjustment for the variables listed in Additional File
1 had little or no impact on the effect estimates in any pro-
cedure group. Furthermore, of all potential confounders
studied, only duration of the operation was significantly
or borderline significantly correlated to the rate of SSI (p
= 0.04 in hysterectomies and p = 0.05 in intestinal resec-
tions).
Subgroup analysis
In subgroup analyses of intestinal resections (figure 1),
the rate of SSI was significantly higher during cephalothin
prophylaxis in rectum resections (JGB procedures). The
crude relative risk of SSI during period 2 (cephalothin)
versus all other periods was 1.98 (95% CI: 1.25 - 3.12)
and the adjusted RR was 2.19 (95% CI: 1.34 - 3.59). Infec-
tion rates were 20.0% and 11.9% during the two periods
of doxycycline treatment (period 1 and 3) and 35.1% dur-
ing cephalothin prophylaxis (period 2).
There was a trend towards a higher RR for SSI in surgery of
the small and large intestine during the periods with
cephalothin prophylaxis compared with the doxycycline
periods (25.6% vs. 18.8% and 18.9%), but this was not
significant (adjusted RR = 1.36, 95% CI: 0.95 - 1.93). The
procedure groups "stoma and pouch procedures" (14
evaluated cases and 5 SSIs) and colectomies (54 evaluated
cases and 11 SSIs) were too small for independent analy-
sis.
Table 2: Patient group and characteristics according to period of observation
Patient group and characteristics Period 1 Period 2 Period 3
Colorectal patients (n)a 518 203 165
Patient's age (median) 68.0 70.0 65.0
Women (%) 49.0 46.8 49.7
ASA score (median) 2.0 2.0 2.0
Emergency procedure (%) 37.5 33.0 23.6
Day-time operation (%) 81.1 84.2 87.9
Operation time (median) 151 145 142
Gynaecology patients (n)b 365 153 137
Patient's age (median) 53.0 55.0 55.0
Women (%) 100 100 100
ASA score (median) 1.0 2.0 2.0
Emergency procedure (%) 1.64 1.31 1.46
Day-time operation (%) 97.5 100 99.3
Operation time (median) 100 117 115
Obstetric (control) patients (n)c 915 334 240
Patient's age (median) 31.0 31.0 31.0
Women (%) 100 100 100
ASA score (median) 1.0 2.0 2.0
Emergency procedure (%) 68.1 74.6 80.4
Day-time operation (%) 53.9 56.0 49.6
Operation time (median) 35.0 38.0 36.0
a Colorectal procedures include all operations with resection of small or large intestine performed at the colorectal department.
b Gynaecology procedures include excision of the uterus.
c Obstetric procedures include acute and elective caesarean sections.Page 4 of 7
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This is a cohort study measuring the effect of changes in
the recommendations for antibiotic prophylactics on an
intention to treat basis. The results are convincing, as there
is a good time relation between shift of recommendations
for antibiotic prophylaxis and change in the SSI rate espe-
cially in the high-risk procedures like rectal resections. The
results from the colorectal department are especially con-
vincing, as shifts from doxycycline to cephalothin and
back again were monitored. The SSI rate of caesarean sec-
tions increased non-significantly during the observation
period. This further indicates that the observed changes in
SSI for colorectal surgery may be related to the type of
antibiotic used.
The infection rates during doxycycline prophylaxis are low
compared with other published results taking into
account that this is a non-selected patient population
including all procedures on an intention to treat basis, not
excluding high risk patients or cases with protocol viola-
tions. The number of patients is high and allowed precise
effect estimates overall as well as in some subgroups.
There is an increase in SSI risk during cephalothin proph-
ylaxis in intestinal surgery. The half-life of cephalothin is
approximately 45 minutes compared to a half-life of 16-
18 hrs for doxycycline. This short half-life renders patients
receiving cephalothin prophylaxis vulnerable to protocol
violations, which are known to be common and which
happened in 27% of the cases [12,16]. Intravenous antibi-
otic prophylaxis should be administered 30-60 minutes
prior to the operation. In the colorectal department
patients received prophylaxis before they left the ward 55
minutes before the operation but 75 minutes before the
operation for patients who had epidural catheter before
surgery. The frequency of SSI could probably be reduced
by reducing the number of protocol violations, and focus
should be addressed to this. It is however well known that
violations occur in the routine setting and it might be
attractive to reduce this risk by using drugs with a longer
half-life.
Duration of the procedure was the only factor amongst
those monitored which was significantly related to the SSI
rate. A significant increase in RR of SSI in long lasting pro-
cedures is well known [20]. It is therefore possible that
Table 3: Relative risks, with 95% confidence intervals, of SSI for periods with cephalothin and metronidazole relative to periods with 
doxycycline and metronidazole
Patient group Periods Crude
RRa
95% CI Adjusted
RRb
95% CI
Colorectal patientsc 2 versus 1 and 3 1.60 1.23, 2.09 1.61 1.22, 2.12
2 versus 1 1.56 1.18, 2.06 1.57 1.18, 2.19
2 versus 3 1.74 1.17, 2.60 1.74 1.15, 2.62
Gyneacology patientsd 2 and 3 versus 1 1.10 0.75, 1.62 0.98 0.64, 1.49
a Calculated by using log-binomial regression models.
b Adjusted for age, gender, surgical procedure, ASA score, emergency procedure, time of operation and operation time.
c Period 1 was the first period of treatment with doxycycline and metronidazole. Period 2 was the period when cephalothin and metronidazole was 
used, and period 3 was the period when we returned to doxycycline and metronidazole.
d Period 1 was the first period of treatment with doxycycline and metronidazole. Cephalothin and metronidazole was used throughout period 2 and 
3 (i.e., did not return to doxycycline and metronidazole in period 3).
SSI rates according to patient group and period of observa-tionFigur  1
SSI rates according to patient group and period of 
observation. Period 1 was the first period of treatment 
with doxycycline and metronidazole (white bars). Period 2 
was the period when cephalothin and metronidazole was 
used (grey bars). Period 3 was the period when we returned 
to doxycycline and metronidazole (black bars). The gynaecol-
ogy department continued use of cephalothin and metronida-
zole during period 3 (i.e., same regimen during period 2 and 
3). The obstetric (control) patients did not change the antibi-
otic regimen during the study period (i.e., hatched bars). 
Detailed data are provided in Additional File 2.Page 5 of 7
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istrations after 3 hours could reduce the SSI rate if cepha-
lothin is used for prophylaxis. The 30-day SSI rate
observed with cephalothin is, on the other hand, compa-
rable to other rapports [1,3] and was consistently found to
be reduced during doxycycline prophylaxis in 2 different
departments with 2 different protocols for administra-
tion. Procedures for rectal surgery came out with the high-
est SSI. This is in accordance with the findings of Konishi
et al [21].
It may seem surprising that the frequency of SSI during
doxycycline-metronidazole prophylaxis is lower after rec-
tal resections than after colon- and small intestinal resec-
tions. The frequency of acute procedures is, however low
in the rectal resections and the level of experience of the
principal surgeon higher. This cannot be verified by our
data.
In the department of gynaecology, the difference in SSI
during the 2 regimens is not significant.
Conclusion
This study suggests that doxycycline in combination with
metronidazole is a candidate that should be considered
for prophylaxis in moderate and major size procedures in
colorectal and small intestinal surgery and possibly in
gynaecological procedures. It reduces the frequency of SSI
in colorectal and small intestinal surgery and is compara-
ble in effect with cephalothin in the other procedures. It is
known as a safe drug causing few clinically important side
effects.
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